Chapter 3: Pharmacodynamics — Module 1: The Receptor Concept, Binding Kinetics and Drug-Receptor Interaction
1. A 58-year-old man with stable ischemic heart disease on aspirin 81 mg daily requires urgent dental extraction. His dentist recommends ibuprofen for post-procedure analgesia. His cardiologist raises concern about a drug interaction that could negate aspirin's cardioprotective antiplatelet effect. Which of the following best describes the pharmacodynamic basis for this concern?
A) Ibuprofen irreversibly inhibits cyclooxygenase-1 (COX-1) through the same covalent mechanism as aspirin, so concurrent use doubles the duration of COX-1 inhibition and increases bleeding risk without adding cardioprotection
B) The interaction is purely pharmacokinetic -- ibuprofen reduces aspirin's oral bioavailability by competing for intestinal absorption transporters, preventing sufficient aspirin from reaching the systemic circulation to acetylate platelet COX-1
C) Ibuprofen and aspirin act at different sites on COX-1 -- aspirin acetylates Ser530 while ibuprofen binds Arg120; when taken together, the two drugs block complementary access channels and produce synergistic COX-1 inhibition that paradoxically reduces rather than enhances platelet aggregation
D) Ibuprofen is a reversible competitive inhibitor of COX-1 that binds the same active-site channel that aspirin must access to acetylate Ser530; if ibuprofen is taken before aspirin, it sterically blocks aspirin's access to the serine residue, preventing acetylation; because ibuprofen's inhibition is reversible, it eventually dissociates but aspirin has already been cleared from plasma -- leaving COX-1 uninhibited and platelet aggregation intact
E) Ibuprofen displaces aspirin from plasma protein binding sites, transiently raising free aspirin concentrations to toxic levels that paradoxically inhibit thromboxane synthesis in the vascular endothelium rather than in platelets, reducing cardioprotection
ANSWER: D
Rationale:
This is a clinically important pharmacodynamic interaction based on the mechanism of aspirin's irreversible COX-1 inhibition. Aspirin must physically access the hydrophobic channel leading to the active-site serine (Ser530) to transfer its acetyl group. Ibuprofen, as a reversible competitive COX-1 inhibitor, binds within this same channel. If ibuprofen is present in the channel when aspirin arrives, aspirin cannot reach Ser530 and acetylation does not occur. Because aspirin has a short plasma half-life (15-20 minutes for the parent compound), it is cleared from plasma before ibuprofen dissociates from the channel. When ibuprofen eventually leaves the receptor, the COX-1 serine is un-acetylated and platelet aggregation capacity is intact. The result is that the patient has taken aspirin but received no lasting antiplatelet protection -- the ibuprofen has effectively nullified the aspirin dose. The clinical solution is to take aspirin first (at least 30 minutes before ibuprofen) to allow acetylation before ibuprofen occupies the channel, or to use an analgesic that does not compete for COX-1 (such as acetaminophen or selective COX-2 inhibitors). This interaction was confirmed clinically in studies showing that regular ibuprofen use in aspirin-treated cardiovascular patients is associated with increased cardiovascular events.
Option A: Option A is incorrect -- ibuprofen does not irreversibly inhibit COX-1; it is a reversible inhibitor; irreversibility is the defining pharmacological feature of aspirin.
Option B: Option B is incorrect -- the interaction is pharmacodynamic, not pharmacokinetic; aspirin's absorption is not affected by ibuprofen at the intestinal level.
Option C: Option C is incorrect -- aspirin and ibuprofen both access the same COX-1 active-site channel; they do not act at complementary distinct sites producing synergistic inhibition.
Option E: Option E is incorrect -- plasma protein binding displacement by ibuprofen is not the mechanism; free aspirin concentration changes from protein binding displacement are transient and clinically insignificant; the channel-blocking mechanism is the established explanation.
2. A 72-year-old woman with Alzheimer's disease is started on donepezil, a reversible acetylcholinesterase inhibitor. She is already taking memantine, an NMDA receptor antagonist. A medical student asks whether donepezil could interact with memantine at the receptor level, since both drugs affect cholinergic neurotransmission. Which of the following best addresses the student's question?
A) No -- donepezil acts at acetylcholinesterase (an enzyme) in the cholinergic synapse while memantine acts at NMDA glutamate receptors; these are pharmacologically distinct molecular targets with no direct interaction; the two drugs complement each other through independent mechanisms -- donepezil increases cholinergic neurotransmission while memantine reduces excitotoxic glutamatergic overactivation -- and the combination is a standard, evidence-based treatment approach for moderate-to-severe Alzheimer's disease
B) Yes -- donepezil increases synaptic acetylcholine, which activates M1 muscarinic receptors on glutamatergic neurons, increasing glutamate release; this increased glutamate competes with memantine for NMDA receptor binding, reducing memantine's neuroprotective efficacy
C) Yes -- elevated synaptic acetylcholine from donepezil activates nicotinic receptors on glutamatergic presynaptic terminals, increasing glutamate release and overwhelming memantine's NMDA channel block, producing net excitotoxicity despite the presence of memantine
D) No -- both drugs bind only post-synaptic receptors and there are no known pre-synaptic interactions between acetylcholinesterase inhibitors and NMDA antagonists in Alzheimer's disease pathways
E) Yes -- acetylcholinesterase inhibition by donepezil raises synaptic acetylcholine to concentrations that directly displace memantine from the NMDA receptor channel through competitive kinetics, since both molecules are positively charged and compete for the same intrachannel binding site
ANSWER: A
Rationale:
This question tests understanding of receptor selectivity and drug target identity. Donepezil is an acetylcholinesterase inhibitor -- it inhibits the enzyme that degrades acetylcholine in the synapse, thereby increasing synaptic acetylcholine concentration and prolonging its action at muscarinic and nicotinic receptors. Memantine is an uncompetitive NMDA receptor antagonist -- it enters the open NMDA channel and blocks it in a voltage- and use-dependent manner, reducing excessive glutamatergic stimulation (excitotoxicity) believed to contribute to Alzheimer's neurodegeneration. These drugs act at completely different molecular targets: donepezil at an enzyme (AChE), memantine at an ion channel receptor (NMDA). There is no pharmacodynamic interaction at the receptor level because they do not share a target. The combination is in fact the standard of care for moderate-to-severe Alzheimer's disease, supported by clinical trial evidence demonstrating additive cognitive benefit when both mechanisms are engaged simultaneously. The student's concern, while showing appropriate pharmacological thinking, misidentifies a connection that does not exist at the molecular level.
Option B: Option B is incorrect -- while increased cholinergic tone can modulate glutamate release indirectly, this does not produce clinically meaningful competition with memantine at NMDA receptors; the combination remains effective.
Option C: Option C is incorrect -- while nicotinic receptor activation can influence glutamate release, the clinical evidence demonstrates that the combination is beneficial rather than producing net excitotoxicity.
Option D: Option D is incorrect -- donepezil acts at a pre-synaptic enzyme (AChE is present at the synapse), not exclusively at post-synaptic receptors; the statement contains a factual error about drug localization.
Option E: Option E is incorrect -- acetylcholine does not bind NMDA receptors; acetylcholine and memantine bind completely different receptor classes; there is no competitive kinetics between them at the NMDA channel.
3. A pharmaceutical scientist presents data on two mu-opioid receptor agonists. Drug Alpha has a Kd of 2 nM and an EC50 of 1.8 nM in a guinea pig ileum contraction assay. Drug Beta has a Kd of 10 nM and an EC50 (the concentration producing 50% of maximum effect) of 0.1 nM in the same assay. Which of the following correctly interprets this data?
A) Drug Alpha is more potent than Drug Beta because its EC50 is closer to its Kd, indicating that it has no wasted receptor occupancy and drives the maximum receptor response at the most efficient concentration
B) Drug Alpha has both higher affinity and higher functional potency and would therefore be the preferred analgesic in all clinical situations where opioid analgesia is required
C) Drug Beta's EC50 being far below its Kd indicates that the guinea pig ileum has a very large receptor reserve for mu-opioid agonists; maximum contraction is achieved when only approximately 1% of receptors are occupied (EC50/Kd ratio of 0.01), meaning 99% of mu-opioid receptors in this tissue are spare receptors; Drug Beta is functionally more potent than Drug Alpha despite having lower receptor affinity
D) Drug Beta's data are internally inconsistent -- a drug with lower receptor affinity (higher Kd) cannot have a lower EC50 than a drug with higher receptor affinity; the data must contain an experimental error
E) The Kd values are irrelevant to clinical drug development -- only functional EC50 values matter for drug selection, and Drug Beta's superior functional potency makes it categorically preferable regardless of its lower binding affinity
ANSWER: C
Rationale:
This question requires integration of binding and functional pharmacodynamic concepts to reach a correct interpretation. Drug Alpha has a Kd of 2 nM and EC50 of 1.8 nM -- these values are nearly identical, indicating that the functional potency closely tracks binding affinity; there is minimal receptor reserve in the assay for Drug Alpha, or Drug Alpha has limited intrinsic efficacy such that it requires near-maximal occupancy to produce half-maximal effect. Drug Beta has a Kd of 10 nM (lower affinity than Alpha) but an EC50 of 0.1 nM -- 100-fold lower than its Kd. This large discrepancy between binding affinity and functional potency is the pharmacodynamic signature of a large receptor reserve in the tissue. If EC50/Kd = 0.01, then maximum effect is achieved when approximately 1% of receptors are occupied (the remaining 99% are spare). Drug Beta is functionally more potent than Drug Alpha despite its lower receptor affinity, because the tissue amplifies Drug Beta's signal so efficiently through receptor reserve that very low occupancy produces near-maximum response. This illustrates a fundamental teaching point: functional potency (EC50) is not the same as receptor affinity (Kd), and a drug with lower affinity can be more potent in a tissue with large receptor reserve. Clinically, this also explains why receptor reserve provides a safety margin -- even if receptor density declines through disease or aging, functional responses can be maintained.
Option A: Option A is incorrect -- a small EC50/Kd ratio for Drug Alpha indicates absence of receptor reserve or low efficacy, not efficiency; it means Alpha requires near-full occupancy for half-maximal effect, which is pharmacodynamically less favorable.
Option B: Option B is incorrect -- Drug Beta has superior functional potency (lower EC50) despite lower affinity; Drug Alpha is not preferable in all situations.
Option D: Option D is incorrect -- there is no internal inconsistency; receptor reserve explains exactly why a lower-affinity drug can have greater functional potency in a tissue with abundant spare receptors.
Option E: Option E is incorrect -- Kd values are not irrelevant; they determine how receptor occupancy changes with drug concentration and are essential for understanding pharmacodynamic interactions, competitive antagonism, and the mechanism of receptor reserve.
4. A 55-year-old man with a pheochromocytoma is prepared for surgical resection with phenoxybenzamine starting 10-14 days before surgery. During tumor manipulation intraoperatively, a massive catecholamine surge occurs producing severe hypertension. The anesthesiologist considers whether a large bolus of intravenous phentolamine (a competitive reversible alpha-blocker) could overcome the phenoxybenzamine block and reduce blood pressure. Which of the following correctly addresses this question?
A) Yes -- once phenoxybenzamine is discontinued 24 hours before surgery, competitive receptor displacement by phentolamine becomes possible because phenoxybenzamine's irreversible block has largely reversed by the time of surgery
B) Yes -- but very high doses of a direct alpha-agonist such as norepinephrine will be required to displace both phenoxybenzamine and phentolamine from the receptor, restoring vascular tone if blood pressure falls excessively
C) Yes -- phenoxybenzamine's block is surmountable at very high catecholamine concentrations because the covalent bond becomes thermodynamically unstable at physiological temperatures when receptor occupancy by endogenous agonists exceeds 90%
D) Yes -- phenoxybenzamine's block is irreversible only during active drug administration; once the drug is cleared from plasma, the covalent bond hydrolyzes spontaneously within hours, restoring receptor sensitivity to competitive antagonism
E) No -- phenoxybenzamine's irreversible covalent block cannot be overcome by any concentration of competitive antagonist or agonist; phentolamine can only occupy receptors not already blocked by phenoxybenzamine; the hypertension from catecholamine surge during pheochromocytoma resection is managed by the pre-operative phenoxybenzamine block (which protects against alpha-mediated vasoconstriction) combined with intraoperative phentolamine to block any remaining unoccupied alpha receptors and nitroprusside for additional vasodilation if needed
ANSWER: E
Rationale:
Phenoxybenzamine produces irreversible alpha-adrenergic receptor blockade through covalent bond formation. By definition, irreversible block cannot be surmounted -- no concentration of competing ligand (agonist or competitive antagonist) can displace a covalently bound molecule from its receptor. The alpha receptors blocked by phenoxybenzamine are pharmacologically dead for the life of that receptor protein, and recovery requires synthesis of new receptor. This pharmacodynamic principle has direct clinical implications in pheochromocytoma management. The 10-14 day pre-operative phenoxybenzamine course is designed to irreversibly block a large proportion of alpha-adrenergic receptors so that the massive catecholamine surge during tumor manipulation cannot produce life-threatening vasoconstriction, regardless of how high catecholamine concentrations rise. Phentolamine administered intraoperatively provides additional alpha-blockade at receptors not already occupied by phenoxybenzamine. Sodium nitroprusside provides non-receptor-mediated vasodilation as further backup. The management strategy explicitly relies on the irreversibility of phenoxybenzamine's block -- if the block were surmountable, the catecholamine surge (which can produce norepinephrine concentrations orders of magnitude above normal) would overcome it.
Option A: Option A is incorrect -- phenoxybenzamine is typically continued until the day before or day of surgery; even if discontinued, the covalent block does not reverse on a 24-hour timescale; recovery requires new receptor synthesis over days.
Option B: Option B is incorrect -- norepinephrine cannot displace a covalently bound molecule; this option fundamentally misunderstands the nature of irreversible blockade.
Option C: Option C is incorrect -- covalent bonds do not become thermodynamically unstable based on receptor occupancy by endogenous agonists; this mechanism has no pharmacological basis.
Option D: Option D is incorrect -- phenoxybenzamine's covalent bond does not hydrolyze spontaneously upon drug clearance from plasma; the irreversibility persists until receptor turnover.
ANSWER KEY: Q1=D Q2=A Q3=C Q4=E
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.